Apollomics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Pleasanton CA United States (2016)

Organization Overview

First Clinical Trial
2017
NCT03053466
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Apollomics Inc. | CBT Pharmaceuticals (Australia) Pty Ltd | CBT Pharmaceuticals, Inc. | EVP and Chief Operating Officer, CBT Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

uproleselan (2 trials)

Drugs in Phase 2 Trials (4)

apl-101 (3 trials)

apl-501 (1 trial)

nivolumab (opdivo) (1 trial)

osimertinib (tagrisso) (1 trial)

Drugs in Phase 1 Trials (4)

apl-102 (1 trial)

cbt-101 (1 trial)

genolimzumab (1 trial)

plb1001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinosarcoma (Phase 1)

Glioblastoma (Phase 1)

Kidney Neoplasms (Phase 1)

Liver Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Microsatellite Instability (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Unknown Primary (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 9